

Cite this: *Chem. Sci.*, 2025, 16, 199

All publication charges for this article have been paid for by the Royal Society of Chemistry

A switchable magnetic resonance imaging nanoplatform for *in situ* microRNA imaging†

Yan Tan,^a Junren Wang,^a Qian Wan,^b Jinlong Yang,^a Jinkun Huang,^a Zijia Zhou,^a Haifeng Dong^{*,a} and Xueji Zhang^{*ac}

Aberrant microRNA (miRNA) expression is associated with various types of carcinogenesis, making miRNA a promising candidate for diagnostic and therapeutic biomarkers. However, *in situ* miRNA diagnostics remains a significant challenge owing to the various biological barriers. Herein, we report a novel miRNA imaging probe consisting of PEG-polylysine-PNIPAM polymer matrix-modified small Fe₃O₄ (PAA-Fe₃O₄-DNA@PPP) nanoparticles with an improved circulatory half-life, efficient tissue permeability, and enhanced tumor accumulation, for *in situ* miRNA magnetic resonance imaging (MRI). In this strategy, we employed large size PAA-Fe₃O₄-DNA@PPP to improve circulatory time and utilized PEG-polylysine-PNIPAM as a GSH-responsive moiety to dissociate PAA-Fe₃O₄-DNA@PPP and release small size PAA-Fe₃O₄-DNA for enhanced tumor permeability. Specifically, the target miRNA acts as a cross-linker for PAA-Fe₃O₄-DNA, forming larger assemblies that not only amplify the MRI signal for detection but also enhance retention for prolonged observation. Both the *in vitro* and *in vivo* results validate that the imaging probe exhibits an enhanced MRI signal with 3.69-fold amplification for tumor interior miRNA detection, allowing the dynamic changes in miRNA to be monitored by the probe. Given its long circulation, efficient penetration, and enhanced tumor accumulation, the PAA-Fe₃O₄-DNA@PPP probe holds great promise for *in situ* miRNA imaging and spatial genomics analysis *in situ*.

Received 14th July 2024

Accepted 14th November 2024

DOI: 10.1039/d4sc04675g

rsc.li/chemical-science

Introduction

In situ biomarker imaging that utilizes advanced imaging techniques such as microscopy, magnetic resonance imaging (MRI), or positron emission tomography (PET) to identify and monitor these biomarkers within their natural environment, holds great promise for personalized medicine in cancer diagnosis and advancing our understanding of the complex pathological process. However, several challenges and limitations persist in efficiently delivering imaging agents to tumor tissue to achieve optimal efficacy. As reported, nanoparticles (NPs) with a diameter of 100 nm can be stable in the circulation, but not efficiently pass through tumor vessels.¹ In contrast, small-size NPs with an approximate size of 4–20 nm easily penetrate through deep tumor tissues, yet they are more inclined to

clearance and lack retention at tumor sites.² Therefore, rational designs of NPs with size-tunable performance under various biological conditions to achieve effective tumor accumulation and enhanced tumor permeability have been continuously developed.^{3–5}

As a significant small non-coding RNA molecular, microRNA (miRNA) is the post-transcriptional regulator in biological and pathological effects, especially serving as a crucial biomarker for tumor classification.^{6–8} In our previous studies, selective and sensitive detection of miRNA in living cells based on nanoparticle systems has been developed.^{9–11} *In situ* miRNA detection is vital for biological function and mechanism research and monitoring of cancerous pathological conditions; however, it is still a huge challenge because of their low-abundant expression level and complex biological environments. Photoacoustic imaging (PAI) of miRNA at the tumor site was realized *via* miRNA-triggered self-assembly of DNA-coated nanostructures to form particle aggregation with enhanced PAI signals.¹¹ A cancer cell membrane camouflaged nanoprobe with homotypic-targeting capability and remarkable amplification was also designed for PAI of miRNA in living mice.¹² Smartly designed hierarchical nanoparticles with size-tunable properties in response to physiological conditions to satisfy long circulation, efficacy permeability and tumor site-specific miRNA activatable signal enhancement have never been reported.

^aMarshall Laboratory of Biomedical Engineering, Precision Medicine and Health Research Institute, Research Center for Biosensor and Nanotheranostic, Guangdong Key Laboratory of Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China. E-mail: hfdong@szu.edu.cn; zhangxueji@szu.edu.cn

^bPaul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advance Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

^cGuangdong Laboratory of Artificial Intelligence and Digital Economy (SZ), Shenzhen, 518060, China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4sc04675g>



Magnetic resonance imaging (MRI) has been proven as a mighty appliance for clinical diagnosis because of its resultful tissue contrast, high spatial resolution (about 50 μm), low ionizing radiation, and unstinted signal penetration depth.^{13–16} Thereinto, ultrasmall superparamagnetic iron oxide nanoparticles (IONPs) with appreciable biodistribution and metabolism have been widely used as T_1 -weighted MRI contrast agents.^{17,18} Interestingly, previous studies reported that the assemblies of IONP contrast agents dramatically affected the magnetic properties due to the aggregation-induced enhancement of the magnetic field resulting in T_2 contrast imaging promotion.^{19–22} Such properties provided great opportunities to establish conditional activatable contrast agents that could further amplify the imaging contrast by abating the interference generated from nonspecific adsorption or endogenous iron-derived imaging contrast.²³ A series of transformations of IONPs exhibited an excellent capacity for penetration and aggregation in the physiological environment and have been developed to evaluate deep tumor imaging in clinical applications.²⁴ For example, “turn-on” MRI nanoprobes were fabricated that showed dark T_2 contrast imaging in the vessels and transformed into bright T_1 contrast imaging owing to GSH or pH-triggered cleavage in the tumor microenvironment (TME).^{25–28} Smart switchable MRI probes based on the self-assembly of IONPs were fabricated as a transformation from T_2 -weighted into T_1 -weighted contrast imaging at the tumor site under low pH-induced disassembly.²⁹ However, multistep switchable MRI probes for *in situ* miRNA imaging have scarcely been explored.


Therefore, for the first time, we designed a “large-small-large” size-switchable PAA- Fe_3O_4 -DNA@PPP nanoplatform, consisting of PEG-polylysine-PNIPAM polymer matrix-modified small Fe_3O_4 , for *in situ* miRNA imaging. As shown in Scheme 1, PAA- Fe_3O_4 -DNA@PPP maintains a large size for prolonged circulation time; it decomposes to a small size (4–5 nm) PAA- Fe_3O_4 -DNA exposing to TME GSH conditions for deep

penetration. After the internalization of PAA- Fe_3O_4 -DNA, the small-size nanoparticles would be linked by the intracellular miRNA to self-assemble to form stable larger-size nanoparticles (more than 50 nm) that consequently enhance the T_2 -weighted MRI in the tumor for miRNA *in situ* detection. Meanwhile, fluorescent dye Cy5 was conjugated on the DNA strand to track the nanosystem accurately. The size switchable imaging system is anticipated to be applied to plenty of *in situ* biomolecular detections by rational detection probe design.

Results and discussion

“Small-to-large” PAA- Fe_3O_4 -DNA@PPP assembly

The construction procedure of PAA- Fe_3O_4 -DNA@PPP is presented in Scheme 1. First, polyacrylic acid-modified Fe_3O_4 (PAA- Fe_3O_4) nanoparticles were synthesized according to the previous method with the hydrothermal decomposition in the existence of polyacrylic acid and ferric chloride raw materials.³⁰ The average diameter of PAA- Fe_3O_4 , as measured by transmission electron microscopy (TEM) is about 4.43 ± 0.6407 nm (Fig. 1a and S1†). The high resolution TEM measurement of PAA- Fe_3O_4 shows that the lattice fringe spacing value is 0.262 nm, which is assigned to the (311) planes of Fe_3O_4 (inset of Fig. 1a). Fourier transform infrared spectrometry (FTIR) was chosen to confirm the carboxyl group of PAA conjugated on Fe_3O_4 . The peak at 1639 cm^{-1} is due to the C=O bond in the PAA.³¹ On the other hand, the vibration absorption peaks (3300 cm^{-1}) for the O–H bond demonstrated that PAA- Fe_3O_4 was successfully synthesized (Fig. S2†). Additionally, the peak at around 580 cm^{-1} represented the vibration of FeO groups.³² Two fluorescent dye-labeled single-strand DNA sequences complementary to target miRNA were conjugated on PAA- Fe_3O_4 *via* the



Scheme 1 Illustration of size-flexible PAA- Fe_3O_4 -DNA@PPP for MRI activated by miRNA. (a) Large-size PAA- Fe_3O_4 -DNA@PPP is formed by coating the polymer PPP in the core of DNA-modified Fe_3O_4 nanoparticles. (b) PAA- Fe_3O_4 -DNA@PPP degrades into small size PAA- Fe_3O_4 -DNA exposed to GSH and low pH in the TME. (c) The small size PAA- Fe_3O_4 -DNA is taken up *via* cellular endocytosis and then assembled into a larger complex linked by the miRNA with an enhanced T_2 MR signal.




Fig. 1 Preparation and characterization of PAA- Fe_3O_4 -DNA and the miRNA assemble aggregate. (a) TEM image of the PAA- Fe_3O_4 nanoparticles; the inserted panel shows the distribution profile of the average size of PAA- Fe_3O_4 nanoparticles. (b) Scheme illustration for miRNA-21 triggering the PAA- Fe_3O_4 -DNA assembly. (c) Photos of Cy5 and Cy3 labeled DNA conjugated PAA- Fe_3O_4 . (d) The ζ potential of PAA- Fe_3O_4 -DNA@PPP based samples. 0.5:1, 1:1, 1.5:1 and 2:1 groups represent the N/P ratios of PPP and PAA- Fe_3O_4 -DNA. (e) TEM image of PAA- Fe_3O_4 -DNA@PPP with a 1.5 N/P ratio.



amino-carboxyl group crosslinking reaction to form PAA-Fe₃O₄-DNA1 and PAA-Fe₃O₄-DNA2 (Fig. 1b to c). After the conjugation, the extra fluorescent DNA was removed with the help of a magnet (Fig. S3†). The successful modification of DNA molecules on PAA-Fe₃O₄ was determined *via* UV spectra at 260 nm (Fig. S4†). The amount of DNA1 and DNA2 on PAA-Fe₃O₄ was estimated to be 13.74 μmol g⁻¹ Fe and 11.88 μmol g⁻¹ Fe, respectively, according to the standard curve of fluorescence and concentration (Fig. S5†). These results suggested that the DNA was successfully conjugated on PAA-Fe₃O₄. To protect the PAA-Fe₃O₄-DNA nanoparticles, multiblock cationic polymer PEG-polylysine-PNIPAM (PPP) was synthesized subsequently. Polyethyleneglycol (PEG) modified polycationic polylysine (Plys) (PEG-PLys-SH) (Fig. S6†) and poly(*N*-isopropyl acrylamide) (PNIPAM) grafted Plys (PNIPAM-Plys-SH) (Fig. S7†) were prepared according to the previously reported method.³³ The resulting polymers were characterized by ¹H NMR, and the number of -SH was calculated to be 1.25 and 7 for PEG-PLys-SH (Fig. S8†) and PNIPAM-Plys-SH (Fig. S9†).

The assembly of PAA-Fe₃O₄-DNA@PPP was optimized with different N/P ratios derived from PPP and PAA-Fe₃O₄-DNA. The zeta potential analysis confirmed that the PPP polymer was positive, and the negative charge of PAA-Fe₃O₄-DNA was neutralized as the N/P ratios increased (Fig. 1d). Agarose gel electrophoresis showed that the PAA-Fe₃O₄-DNA@PPP samples were gradually trapped in the beginning line of the gel as the N/P ratios increased, and no free PAA-Fe₃O₄-DNA was visualized at a ratio of 1.5 : 1 (Fig. S10†). These results indicated that the negatively charged DNA has effectively condensed into the PPP polymer. As shown in Fig. 1e, the average diameter of PAA-Fe₃O₄-DNA@PPP is 82 ± 20 nm while the N/P ratio is 1.5. As reported, the PPP polymer would have a relatively smaller size when at a physiological temperature of 37 °C because of thermally responsive PNIPAM.³⁴ When the temperature increases, PNIPAM could transform into the hydrophobic phase that provides an additional drive force to stimulate further condensation of PAA-Fe₃O₄-DNA@PPP and protect PAA-Fe₃O₄-DNA from enzymatic degradation in the physical environment. The high-resolution TEM image and the element mapping analysis indicated that PAA-Fe₃O₄-DNA was encapsulated into the PPP polymer structure (Fig. S11 & S12†).

“Large-to-small” and “small-to-large” transformation

PPP was obtained by disulfide cross-linking formation of PEG-PLys-SH and PNIPAM-Plys-SH, and the resulting PPP could pack the small DNA-functionalized nanoparticles through electrostatic assemblage between cationic Plys-SH and anionic nucleic acid of PAA-Fe₃O₄-DNA to form PAA-Fe₃O₄-DNA@PPP. The disulfide cross-linking was readily cleaved under acidic and reductive conditions with glutathione (GSH). The existence of an ester bond and amide bond in PPP would accelerate the hydrolysis of PAA-Fe₃O₄-DNA@PPP nanocapsule in the acidic TME. The degradation of PAA-Fe₃O₄-DNA@PPP was evaluated by exposing it to GSH with different concentrations of 0 mM, 10 mM, 20 mM, 40 mM, and 80 mM (Fig. 2a). The gel electrophoresis results confirmed that PAA-Fe₃O₄-DNA@PPP gradually




Fig. 2 Evaluation of the size change from large to small. (a) Degradation process of PAA-Fe₃O₄-DNA@PPP. Gel electrophoresis of PAA-Fe₃O₄-DNA@PPP after incubating with different concentrations of GSH (0 mM, 10 mM, 20 mM, 40 mM, and 80 mM). (b) TEM image of PAA-Fe₃O₄-DNA@PPP after degradation in the presence of 20 mM GSH for 24 hours. (c) TEM image of PAA-Fe₃O₄-DNA after self-assembly *via* miRNA-21. (d) Zeta potential of PAA-Fe₃O₄-DNA and miRNA (target) triggered aggregation of PAA-Fe₃O₄-DNA (1 + 2 + T).

degraded with the increase in the GSH concentration. In addition, the TEM image showed the disassembly morphology of PAA-Fe₃O₄-DNA@PPP which was marked with red circles (Fig. 2b). These results confirmed the efficient degradation of PAA-Fe₃O₄-DNA@PPP to small PAA-Fe₃O₄-DNA, which was useful for enhanced tumor depth penetration. Using miRNA-21, a tumor-related up-regulated miRNA, as a model target miRNA, we investigated the feasibility of target miRNA-mediated PAA-Fe₃O₄-DNA assembly, leading to a conversion process from small to large size. As anticipated, the PAA-Fe₃O₄-DNA (1 + 2 + T) aggregates exhibited an average size of 50 nm when the concentration ratio of PAA-Fe₃O₄-DNA1, PAA-Fe₃O₄-DNA2, and miRNA-21 was maintained at 1 : 1 : 1 (Fig. 2c). The resulting aggregates displayed more negative zeta potential (Fig. 2d). As the ratio increases from 1 : 1 : 1 to 1 : 1 : 10, the size increases from about 50 nm to 80 nm (Fig. S13†). These results verified that PAA-Fe₃O₄-DNA1 and PAA-Fe₃O₄-DNA2 could be assembled through the bridge miRNA-21, implementing small-size to larger-size transformation.

Penetration evaluation and *in vitro* magnetic resonance imaging

The penetration of PAA-Fe₃O₄-DNA@PPP was investigated by confocal imaging. MCF-7 multicellular tumor spheroids were formed in the agarose-based microwells and reached a diameter of more than 400 μm after culturing for several days according to previous methods.^{35,36} PAA-Fe₃O₄-DNA@PPP labeled with Cy5 in the DNA has efficiently penetrated the MCF-7 multicellular tumor spheroids characterized by confocal imaging through a layer scan model within 10 μm intervals (Fig. 3a). According to the confocal imaging, cross-sectional fluorescence can be observed when the scanning depth of the Z-axis is 100 μm. The three-dimensional fluorescence reconfiguration of multicellular






Fig. 3 Cy5-labeled PAA-Fe₃O₄-DNA@PPP to penetrate the MCF-7 multicellular tumor spheroids measured using a confocal imaging microscope. (a) Confocal imaging of the PAA-Fe₃O₄-DNA@PPP penetration evaluation from 10 μm to 120 μm. The scale bar is 200 μm. (b) The 3D image was stacked using the software. (c) Field-dependent magnetization hysteresis loops of PAA-Fe₃O₄-DNA1 and PAA-Fe₃O₄-DNA2 incubated with miRNA-21 or not. The ratio of PAA-Fe₃O₄-DNA1, PAA-Fe₃O₄-DNA2, and miRNA-21 is 1 : 1 : 1. (d) The r_2 relaxivity of PAA-Fe₃O₄-DNA treated with various concentrations of miRNA-21. (e) The r_2 relaxivity of PAA-Fe₃O₄-DNA1,2@PPP incubated with MCF-7 cells and PAA-Fe₃O₄-DNA1@PPP as a negative control. (f) The bioTEM image of the PAA-Fe₃O₄-DNA1,2@PPP treated MCF-7 cells. The scale bar is 200 nm.

tumor spheroids exposed to PAA-Fe₃O₄-DNA@PPP confirmed the deep penetration (Fig. 3b).

This reported that ultrasmall Fe₃O₄ nanoparticles with a diameter of less than 5 nm have good T₁-MRI contrast function. In contrast, the self-assembled ultrasmall Fe₃O₄ would enhance the magnetic size inducing a higher saturation magnetization, leading to an improved dark T₂ MRI contrast.^{37–39} As seen in , the value of saturated magnetic intensity for PAA-Fe₃O₄-DNA1 increased from 10.5 to 39.8 meu g⁻¹ when assembled with miRNA-21. Interestingly, the magnetic saturation value of PAA-Fe₃O₄-DNA@PPP was 19.5 meu g⁻¹, indicating that PAA-Fe₃O₄-DNA1 and PAA-Fe₃O₄-DNA2 encapsulated into PPP. Furthermore, we measured the T₁ and T₂ relaxation times of PAA-Fe₃O₄-DNA1,2 with or without miRNA-21. The r_1 and r_2 relaxivity of PAA-Fe₃O₄-DNA1,2 in the presence of miRNA-21 was calculated to be 0.28 mM⁻¹ s⁻¹, 250.1 mM⁻¹ s⁻¹, while r_1 and r_2 relaxivity of the PAA-Fe₃O₄-DNA1,2 mixture without miRNA-21 was 0.83 mM⁻¹ s⁻¹ and 101.0 mM⁻¹ s⁻¹ (Fig. S14 & S15[†]). These results suggested that the assembly PAA-Fe₃O₄-DNA1,2 triggered by miRNA-21 showed enhanced T₂ suitable for T₂ MRI contrast imaging. As the miRNA-21 concentration increased from 0 to 250 nM, the r_2 increased from 6 to 20.4 s⁻¹ (Fig. 3d), and the limit of detection

was calculated to be 0.546 nM using T₂-MRI. We further investigated its performance in living cells. PAA-Fe₃O₄-DNA1,2@PPP was incubated with the MCF-7 cells for 8 hours, and PAA-Fe₃O₄-DNA1@PPP was a negative control. Then the cells were all harvested and washed with PBS. After that, the cells were fixed using agarose and were detected under a 3.0 T MR (Fig. S16[†]). Fig. 3e shows a higher r_2 relaxivity in the PAA-Fe₃O₄-DNA1,2@PPP treated cells compared with the PAA-Fe₃O₄-DNA1@PPP incubated cell group. Meanwhile, the r_1 relaxivity was also measured (Fig. S17[†]), and the r_2/r_1 value was respectively calculated to be 46.0 and 112.7 for the PAA-Fe₃O₄-DNA1@PPP and PAA-Fe₃O₄-DNA1,2@PPP treated groups. As shown in Fig. 3f, the large aggregation structures were visualized in the bioTEM image of the PAA-Fe₃O₄-DNA1,2@PPP treated MCF-7 cells, suggesting that target miRNA-21 induced aggregation. The results illustrated that miRNA-21 in the cells would contribute to the aggregation of PAA-Fe₃O₄-DNA.

In vivo magnetic resonance imaging

To investigate the *in vivo* MRI of PAA-Fe₃O₄-DNA@PPP. PAA-Fe₃O₄-DNA@PPP was tail intravenously injected into the MCF-7-bearing mice. The signal was observed after 20 min of injection (Fig. 4a). As indicated in the T₂ weighted MRI, the assembled PAA-Fe₃O₄-DNA@PPP derived T₂ signal reached the maximum at 90 minutes post-injection. Notably, the ratio of the T₂/T₁ signal was less than 1.0 at 20 min after injection (Fig. S18[†]), and the signal increased as time increased, verifying that PAA-Fe₃O₄-DNA@PPP was a good T₂-weighted contrast reagent. Furthermore, to investigate the monitoring ability of miRNA change by PAA-Fe₃O₄-DNA@PPP, miRNA-21 mimics were injected intratumorally for 4 h before the imaging




Fig. 4 (a) T₁-MRI and T₂-MRI images of mice bearing MCF-7 tumor cells according to the intravenous injections of PAA-Fe₃O₄-DNA@PPP. (b) The miRNA-21 mimics were transferred before the intravenous injections of PAA-Fe₃O₄-DNA@PPP, and then the T₁-MRI and T₂-MRI were measured. (c) The Prussian blue dyeing of the tumor tissues after MRI observation. The microscope objective is 10× and 40× for the upper and lower figures. (d) The tumor slices were observed under a fluorescence microscope. The Cy5 FL indicates Cy5 labeled PAA-Fe₃O₄-DNA@PPP. 10×, 20× and 40× represent objectives with different magnification times.



experiment. The mimic DNA sequence has the same function as miRNA-21. The T_1 and T_2 MRI signals were evaluated after being injected for 20 min, 40 min, 60 min, and 90 min. As shown in the T_2 MRI images displayed in Fig. 4b, the hole in the green circle was the injection site. Many dark dots derived from the miRNA-21-induced PAA- Fe_3O_4 -DNA assembly were observed (in red circles).

The tumors were collected for sectioning and staining to verify whether PAA- Fe_3O_4 -DNA@PPP entered into the tissues. Prussian blue dyeing was employed to observe iron. As exhibited in Fig. 4c, the blue granules were in the tumor cells, indicating that PAA- Fe_3O_4 -DNA@PPP could reach the tumor site. Because PAA- Fe_3O_4 -DNA@PPP was labeled with Cy5, the slices were also observed under a fluorescence microscope (Fig. 4d). The mimic miRNA-21-treated tissues displayed strong Cy5 fluorescence compared with that without treatment, which proved that PAA- Fe_3O_4 -DNA was trapped in the tumor tissues with the assistance of the miRNA-induced assembly.

Conclusions

In this work, we report the construction of a switchable miRNA MRI imaging probe, PAA- Fe_3O_4 -DNA@PPP, for *in situ* miRNA imaging. PAA- Fe_3O_4 -DNA@PPP undergoes a “large-small-large” switchable process to cross various biological barriers, accumulate in tumor tissue, and achieve effective *in situ* miRNA MRI imaging. It maintains a large size for prolonged circulation time and then decomposes into small-sized (4–5 nm) PAA- Fe_3O_4 -DNA in response to the TME GSH conditions, allowing for deep penetration. After cellular internalization, the small-sized nanoparticles are linked by intracellular miRNA, self-assembling into stable larger-sized nanoparticles (over 50 nm). This assembly enhances T_2 -weighted MRI signals in the tumor, enabling *in situ* miRNA detection and allowing *in situ* monitoring of the dynamic changes in miRNA. The long circulation time, efficient penetration, and enhanced tumor accumulation make the PAA- Fe_3O_4 -DNA@PPP probe highly promising for *in situ* miRNA imaging and spatial genomics analysis.

Data availability

The data supporting this article have been included as part of the ESI.†

Author contributions

Conceptualization: YT, HFD, and XJZ; experiments and formal analysis: YT, JRW, and QW; methodology: JLY, JKH, and ZJZ; project administration: HFD and XJZ; writing the original draft: YT; writing – review & editing: YT, JRW and HFD. All authors have read and agreed to the final version of this manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The work was supported by the Special Foundation for State Major Research Program of China (grant 2022YFB3207202), the Shenzhen Medical Research Fund (grant 2301011), the Guangdong Province Pearl River Team (2021ZT09C289), and Shenzhen Key Laboratory for Nano-Biosensing Technology (ZDSYS20210112161400001). We thank the Instrumental Analysis Center of Shenzhen University for the assistance with the electron microscope, nuclear magnetic resonance spectroscope, mass spectrometer, confocal microscope, small animal diagnostics imaging, and material characterization technical support.

References

- 1 M. Kyu Shim, S. Yang, I.-C. Sun and K. Kim, *Adv. Drug Delivery Rev.*, 2022, **183**, 114177.
- 2 Z. Niu, L. Liu, L. Zhang, Q. Shao, W. Zhou, X. Chen and S. Xie, *Adv. Mater.*, 2014, **26**, 3681–3687.
- 3 F. Mo, K. Jiang, D. Zhao, Y. Wang, J. Song and W. Tan, *Adv. Drug Delivery Rev.*, 2021, **168**, 79–98.
- 4 B. Chen, L. Liu, R. Yue, Z. Dong, C. Lu, C. Zhang, G. Guan, H. Liu, Q. Zhang and G. Song, *Nano Today*, 2023, **51**, 101931.
- 5 J.-M. Shen, T. Yin, X.-Z. Tian, F.-Y. Gao and S. Xu, *ACS Appl. Mater. Interfaces*, 2013, **5**, 7014–7024.
- 6 P.-Y. Lui, D.-Y. Jin and N. J. Stevenson, *Cell. Mol. Life Sci.*, 2015, **72**, 3531–3542.
- 7 Y. Zhang, W. Chen, Y. Zhang, X. Zhang, Y. Liu and H. Ju, *Angew. Chem., Int. Ed.*, 2020, **59**, 21454–21459.
- 8 C. Xue, S.-X. Zhang, C.-H. Ouyang, D. Chang, B. J. Salena, Y. Li and Z.-S. Wu, *Angew. Chem., Int. Ed.*, 2018, **57**, 9739–9743.
- 9 Y. Zhang, F. Yang, W. Wei, Y. Wang, S. Yang, J. Li, Y. Xing, L. Zhou, W. Dai and H. Dong, *ACS Nano*, 2022, **16**, 5587–5596.
- 10 F. Yang, H. Lu, X. Meng, H. Dong and X. Zhang, *Small*, 2022, **18**, 2106281.
- 11 Y. Tan, J. Zhou, X. Xing, J. Wang, J. Huang, H. Liu, J. Chen, M. Dong, Q. Xiang, H. Dong and X. Zhang, *Anal. Chem.*, 2023, **95**, 11236–11242.
- 12 K. Zhang, X. Meng, Z. Yang, Y. Cao, Y. Cheng, D. Wang, H. Lu, Z. Shi, H. Dong and X. Zhang, *Adv. Mater.*, 2019, **31**, 1807888.
- 13 Z. Liang, Q. Wang, H. Liao, M. Zhao, J. Lee, C. Yang, F. Li and D. Ling, *Nat. Commun.*, 2021, **12**, 3840.
- 14 H. Li, D. Luo, C. Yuan, X. Wang, J. Wang, J. P. Basilion and T. J. Meade, *J. Am. Chem. Soc.*, 2021, **143**, 17097–17108.
- 15 R. Qin, S. Li, Y. Qiu, Y. Feng, Y. Liu, D. Ding, L. Xu, X. Ma, W. Sun and H. Chen, *Nat. Commun.*, 2022, **13**, 1938.
- 16 S. Sheng, F. Liu, M. Meng, C. Xu, H. Tian and X. Chen, *CCS Chem.*, 2022, **4**, 2321–2332.
- 17 Z. Zhou, L. Yang, J. Gao and X. Chen, *Adv. Mater.*, 2019, **31**, 1804567.
- 18 M. Jeon, M. V. Halbert, Z. R. Stephen and M. Zhang, *Adv. Mater.*, 2021, **33**, 1906539.



- 19 H. Zhou, M. Guo, J. Li, F. Qin, Y. Wang, T. Liu, J. Liu, Z. F. Sabet, Y. Wang, Y. Liu, Q. Huo and C. Chen, *J. Am. Chem. Soc.*, 2021, **143**, 1846–1853.
- 20 D. Ling, W. Park, S.-j. Park, Y. Lu, K. S. Kim, M. J. Hackett, B. H. Kim, H. Yim, Y. S. Jeon, K. Na and T. Hyeon, *J. Am. Chem. Soc.*, 2014, **136**, 5647–5655.
- 21 T. A. Meyer, C. Zhang, G. Bao and Y. Ke, *Nano Lett.*, 2020, **20**, 2799–2805.
- 22 T. Liu, M. Zhang, W. Liu, X. Zeng, X. Song, X. Yang, X. Zhang and J. Feng, *ACS Nano*, 2018, **12**, 3917–3927.
- 23 J. Hou, H. Liu, Q. Ma, S. Xu and L. Wang, *Anal. Chem.*, 2022, **94**, 15578–15585.
- 24 R. Yue, C. Zhang, L. Xu, Y. Wang, G. Guan, L. Lei, X. Zhang and G. Song, *Chem*, 2022, **8**, 1956–1981.
- 25 Y. Cao, Z. Mao, Y. He, Y. Kuang, M. Liu, Y. Zhou, Y. Zhang and R. Pei, *ACS Appl. Mater. Interfaces*, 2020, **12**, 26973–26981.
- 26 J. Lu, J. Sun, F. Li, J. Wang, J. Liu, D. Kim, C. Fan, T. Hyeon and D. Ling, *J. Am. Chem. Soc.*, 2018, **140**, 10071–10074.
- 27 J. Xu, G. Guan, Z. Ye, C. Zhang, Y. Guo, Y. Ma, C. Lu, L. Lei, X.-B. Zhang and G. Song, *Sci. Bull.*, 2024, **69**, 636–647.
- 28 M. Ma, H. Zhu, J. Ling, S. Gong, Y. Zhang, Y. Xia and Z. Tang, *ACS Nano*, 2020, **14**, 4036–4044.
- 29 J. Hou, H. Liu, Q. Ma, S. Xu and L. Wang, *Anal. Chem.*, 2022, **94**, 15578–15585.
- 30 S.-H. Huang and D.-H. Chen, *J. Hazard. Mater.*, 2009, **163**, 174–179.
- 31 J. Liu, G. Liu and W. Liu, *Chem. Eng. J.*, 2014, **257**, 299–308.
- 32 J. L. Zhang, R. S. Srivastava and R. D. K. Misra, *Langmuir*, 2007, **23**, 6342–6351.
- 33 O. Veiseh, F. M. Kievit, H. Mok, J. Ayesch, C. Clark, C. Fang, M. Leung, H. Arami, J. O. Park and M. Zhang, *Biomaterials*, 2011, **32**, 5717–5725.
- 34 H. Ding, B. Li, Z. Liu, G. Liu, S. Pu, Y. Feng, D. Jia and Y. Zhou, *Adv. Healthcare Mater.*, 2020, **9**, 2000454.
- 35 L. Wang, J. Li, Z. Zhao, Y. Xia, Y. Xie, D. Hong, Y. Liu and W. Tan, *Anal. Chem.*, 2024, **96**, 154–162.
- 36 F. Zhou, T. Fu, Q. Huang, H. Kuai, L. Mo, H. Liu, Q. Wang, Y. Peng, D. Han, Z. Zhao, X. Fang and W. Tan, *J. Am. Chem. Soc.*, 2019, **141**, 18421–18427.
- 37 W. Liu, S. Yin, Y. Hu, T. Deng and J. Li, *Anal. Chem.*, 2021, **93**, 14223–14230.
- 38 W. Liu, S.-Y. Yin, Y. Hu, T. Deng and J. Li, *ACS Appl. Mater. Interfaces*, 2022, **14**, 2629–2637.
- 39 C. Bai, P. Hu, N. Liu, G. Feng, D. Liu, Y. Chen, M. Ma, N. Gu and Y. Zhang, *ACS Appl. Nano Mater.*, 2020, **3**, 3585–3595.

